Introduction
Phospholipases have been studied in great detail and their role in cell signaling has been established in the last 20 years. A role for phospholipases in mitogenesis has been described in terms of the products of their enzymatic reactions. Lysophosphatidic acid (LPA) is produced by the action of a phosphatidic acid (PA)-specific phospholipase A 2 (PLA 2 ). LPA is a potent mitogen for quiescent fibroblasts and triggers GTP-dependent phosphoinositide breakdown (1) through a membrane receptor (2) . A phosphatidylcholine-specific PLA 2 is responsible for the release of arachidonic acid in response to cell stimulation. Arachidonic acid is the precursor of biologically-active eicosanoids such as prostaglandins, thromboxanes and leukotrienes of key importance in the body's inflammatory response (3) .
Phosphatidylinositol 4,5-bisphosphate (PIP 2 )-specific phospholipase C, associated to membrane G proteins (PLCβ), hydrolyzes PIP 2 to form 1,2-diacylglycerol (DAG) and inositol 1,2,5-trisphosphate (IP 3 ). DAG and IP 3 -generated Ca 2+ are well known agonists of protein kinase C (PKC) activation (4, 5) , and this phospholipid breakdown is one of the earliest key events in the regulation of various cell functions, including cell growth. A phosphatidylcholine-specific PLC, associated to tyrosine kinases, also releases DAG as well as phosphorylcholine. The latter compound is known to be accumulated in the cell during the activation of Raf-1 and mitogen-activated protein (MAP) kinase that follows to growth factor stimulation and mitogenesis (6, 7) . Phosphocholine in conjunction with sphingosine-1-phosphate can greatly stimulate MAP kinase activity (8) .
Phosphatidic acid (PA) is synthesized by the combined action of PLC and a DAG kinase, as well as by a direct action of phospholipase D (PLD) on membrane phospholipids. PA induces a transient intracellular Ca 2+ rise and has growth-factor like effects on cultured cells (9) . The formation of substantial amounts of PA immediately before entry into mitosis is important for establishing a delay in the cell cycle at the G 2 /M border brought about by exogenous ligand (10) . There are alternative pathways for PLC and PLD in regulatory events of intracellular mitogen signaling (11) . In order to be properly divisible, internal membranes must be converted into a vesiculated state prior to mitosis. Due to its membrane-perturbing and fusogenic properties, an increased level of PA in specific membrane compartments may counteract this process and the cell is delayed in the G 2 phase (12) . Activation of PLD by serum is observed during Ras-induced transformation in NIH3T3 fibroblasts (13) . Finally, the other product of PLD action, choline or ethanolamine (depending upon the nature of the membrane phospholipid can also have mitogenic effects. Particularly, ethanolamine analogues stimulate DNA synthesis by a mechanism not involving phosphatidylethanolamine synthesis (14) .
immediately followed by the in vitro microassays alluded to before) in order to study the contribution of a particular isoform within a family of enzymes; and [3] intact-cell or in vivo assays (Subheading 3.3), in which cells are labeled with a radioactive substrate until steady state is reached and then the intact cells are challenged with appropriate stimuli.
In vitro microassays
The uniqueness of the method described here is that it allows the measurement of, in parallel, the activities of three phospholipases utilizing aliquots derived from the same biological sample (FIGURE 1).
The biological sample is prepared as described in detail in Subheading 3.1.1. The cell sonicates generated are then split in three equal aliquots and are utilized for the in vitro microassay methods. These are tailored to the measuring of total activity for: PLA 2 (Subheading 3.1.2), PLC (Subheading 3.1.3) and PLD (Subheading 3.1.4) . The specificity in the method for each phospholipase is conferred by the proper use of a specific substrate, reaction assay buffers and methods of isolation of enzymatic products. All the assays described below are "microassays", i.e., they can be performed in the laboratory using 1.5-ml eppendorf tubes for all the reactions (instead of the traditional large glass test tubes). The small reaction volumes allow for a saving in reagent expenses and processing time. The inclusion of positive controls (like purified enzymes), with known specific activities, is necessary for completeness (15) .
3.1.1. Preparation of the biological sample, or 'source of enzyme'-The very first step in the in vitro microassay protocols is the preparation of the sample from which the three enzyme activities (PLA 2 , PLC and PLD) will be measured.
1.
Resuspend cells in fresh RPMI (culture cells) or Hanks' buffer (neutrophils) in 50 ml conical tubes (blue cap) at a concentration of 0.8-1×10 7 cells/ml (lower range for cultured cells; higher for neutrophils or any other small size cell).
Preincubate with stimuli if needed (see Note 5).
3. Take 1 ml aliquots in triplicate and transfer to pre-chilled eppendorf tubes kept on ice.
4.
Spin down tubes at 1,744xg for 30 seconds and decant supernatant.
5.
Resuspend pellets in 1 ml of each buffer (PLA 2 , PLC or PLD) supplemented with the protease/phosphatase inhibitors (the volume should equate to approximately 500 μl buffer/mg protein).
6.
Sonicate samples on ice (set sonicator at mid-high setting, 2 cycles, 10 seconds per cycle) (see Note 6).
5 Add appropriate cell stimuli (at variable concentration or time of incubation) whose action on the enzyme activity is to be tested. Some phospholipases (like PLA 2 ) will benefit from the presence of calcium in the media. To this end, pre-incubate cells with 1.6 M CaCl 2 at 37 °C for 5 minutes. Since cells tend to sediment, make sure the tube is being rotated properly in the water bath. To stimulate cells, use 1 μl stimulus stock per 1 ml of cells. In this way the stimulus is diluted 1,000 times. Some stimuli might require an intermediate dilution. For example, when using PMA, we usually prepare a μg/ml (in DMSO) stock from which we make a 1:10 dilution in Hanks' buffer right before the experiment. We then add 1 μl per ml of cell suspension (final concentration is 50 ng/ml). All intermediate and final dilutions are discarded after use and never re-frozen. Whenever adding the stimulus to the cell suspension, hold conical tube in hand while swirling it, to facilitate immediate dispersion; add the stimulus very slowly to the suspension going back and forth several times with the pipette to completely release the contents. Place conical tube on bath. 6 As an alternative to sonication, cell lysis can be performed in 'lysis buffer': 12 mM Tris-HCl, pH 7.2; 14 mM NaCl; 0.75 mM EDTA; protease and phosphatase inhibitors as described, and 0.25% Triton X-100. Mix cell pellets with lysis buffer and carry out lysis on ice for 20 minutes with intermittent (every 3-5 min) vortexing. Spin lysates at 13,000 rpm and collect supernatant. We have found (27) that Triton X-100 is inhibitory for PLD, thus, a different detergent must be used. β-octyl-glucopyranoside, in our hands, is appropriate, as long as it is kept at a final concentration of 0.05%, well below its critical micelle concentration (CMC).
7. Do a quick (30 sec) spin (14,000xg) to pull down unbroken cells and other debris. Transfer supernatants to clear eppendorfs labeled 'cell sonicates' and leave on ice until ready to assay. Measure protein concentration (the yield is usually 1-2 mg/ ml). Fifty μl of these sonicates will be needed (per condition) for the in vitro microassays.
3.1.2. PLA 2 in vitro microassay-The first enzymatic assay we will consider is the measurement of PLA 2 activity in cell sonicates. The rate limiting step in eicosanoids synthesis is the release of arachidonic acid. This release involves PLA 2 activation and translocation to the compartments where the substrate (e.g. phosphatidylcholine), is located (16) (17) (18) (19) (20) (21) (22) (23) . The PLA 2 enzyme system is also crucial in the generation of the ether-lipid plateletactivating factor (PAF), a mediator of inflammation. The cytosolic form of PLA 2 (cPLA 2 ), mediates the production of agonist-induced arachidonic acid release, and activation of cPLA 2 requires the phosphorylation of the enzyme, an increase in the concentration of intracellular free calcium, and the translocation to the compartments where the substrates are localized (FIGURE 2).
For in vitro measurements of PLA 2 , the exogenous substrate is a phosphatidylcholine (PC) radiolabeled in the sn-2 position (arachidonic acid). The radiolabeled arachidonic acid (free fatty acid) released after the enzymatic cleavage is purified by TLC. The method indicated below will detect total PLA 2 activity present in the biological sample. For a specific analysis of cytosolic PLA 2 (cPLA 2 ) (24) (see Note 7).
Preparation of liposomes:
1. Label a small unsiliconized glass test tube 'liposomes'; rinse with ddH 2 O and dry. 
4.
Dry lipids under Nitrogen.
5.
Once dry, add 45 μl of PLA 2 buffer and 5 μl calcium solution per condition (final reaction concentration in a 100 μl volume is: 112.5 mM Tris HCl, 5 mM CaCl 2 ).
6. Vortex vigorously; let sit for approximately 10 minutes at room temperature.
7.
Vortex again for 10 seconds; sonicate briefly (sonicator in mid-low setting, 3 cycles of 3 seconds each) on ice. Keep liposomes on ice until needed.
Reaction and lipid separation:
At this point the enzyme (in cell sonicates) is ready to be mixed with the radiolabeled substrate in the optimal conditions of co-factors, ionic strength, pH, etc.
1. To 1.5 ml screw cap tubes, add 50 μl of 'liposomes' (from 3.1.2.1) and 50 μl of 'cell sonicates' (Subheading 3.1.1). 7 The Measurement of cytosolic cPLA 2 activity in vitro can be determined by measuring the amount of arachidonic acid released using 1-stearoyl-2-[1-14 C]arachidonyl-phosphatidylcholine as a substrate (24) . The substrate is dried under a stream of nitrogen and resuspended in DMSO with vigorous vortex-mixing. A known volume of the substrate (2 μl) (final concentration 15 μM) and 5 μl of 16 mM CaCl 2 (final concentration 2 mM) are added to eppendorf microcentrifuge tubes. The reaction is initiated by adding a known volume (33 μl, 30-40 μg protein)) of the cytosolic fraction of cell homogenate. This is obtained by suspending a known number of cells (1-5×10 7 cells) in 1.2 ml lysis buffer. The mixture is sonicated and then centrifuged at 150,000 g for 20 minutes. The supernatant obtained is used to measure cPLA 2 activity. The reaction is carried out for a preset time (5-40 minutes), and it is stopped by adding a known volume (40 μl) of ice-cold quench solution, comprising 40 μg/ml arachidonic acid in ethanol containing 2% (vol/vol) acetic acid. A 40 μl of the solution is spotted on LK5DF silica-gel TLC plates and developed in organic phase of ethyl acetate/iso-octane/ acetic acid/water (55:75:8:100, by volume). The area corresponding to arachidonic acid is revealed by brief exposure to iodine vapor, scraped and the radioactivity is counted.
6. Next, add 2 μl of diluted DOC per condition to the tube (1 mM final).
7.
Vortex vigorously; sonicate briefly (low-mid setting) on ice and keep liposomes on ice until needed.
Reaction and lipid separation:
1. To 1.5 ml screw cap tubes, mix 50 μl of 'liposomes' (Subheading 3.1.3.1) and 50 μl of 'cell sonicates' (Subheading 3.1.1).
2.
Include positive controls (B. cereus PLC pure enzyme) and negative controls (PLC buffer instead of cell sonicates).
3.
Incubate 10 minutes at 30 °C in a orbital shaking incubator at 60 rpm.
4.
Stop the reaction by adding 200 μl of stopping solution to each tube with repeater pipette.
5.
Add 75 μl of Cl 3 CH.
Add 25 μl ddH 2 O.

7.
Cap and vortex each tube vigorously.
8.
Centrifuge at 5,000 rpm for 2 minutes.
9.
Transfer 120 μl of the lower layer (organic phase containing the lipids) to a new set of transfer tubes.
Isolation of the reaction product (radiolabeled DAG):
1. Prepare a "hydrophobic solvent system" and dump it in TLC chamber, cover with lid, and let it sit for a minimum of 1 hour before using it.
2. Spot 30 μl of each lower, organic phase sample (from 3.1.3.2) onto a TLC plate; repeat in rounds until each sample is spotted.
3. Spot 5 μl of each DAG standard onto each plate.
4.
Place the plate in the TLC chamber and run it for about 40 minutes (see Note 9).
5.
Remove plate from the chamber and let it dry.
6. Place plate in iodine chamber to expose standards.
7.
Mark standards (R f of C18:0/C20:4-DAG in this solvent system is ~0.5) and draw lines 1 cm above top standard and 1 cm below standard.
8.
Scrape each lane, place scraped silica into scintillation vial containing 4 ml scintillation cocktail and count samples by scintillation spectrometry (see Note 10).
PLD in vitro microassay-PLD
catalyzes the hydrolysis of membrane phospholipids (such as PC) releasing phosphatidic acid (PA) and a polar head group. In addition to this, in the presence of a primary alcohol (usually ethanol or 1-butanol), PLD can generate a phosphatidylalcohol (phosphatidylethanol (PEt) or phosphatidylbutanol (PBut)) 9 To run a plate in this 'nonpolar' solvent mixture takes approximately 40 minutes, much shorter than other chromatography system, thus it must be watched closely or it will overrun. 10 After plate has run, a zone around (0.5 cm above and below) the application spot (R f ~0) could also be scraped to analyze total [ 14 C] PC. As PC is broken down by PLC to form PA, the amount of PC should decrease.
end-product by what is termed a 'transphosphatidylation' reaction. This reaction is unique to PLD and, as a result, is a commonly used method for measuring PLD activity without the possibility of contamination from other phospholipase activities (chiefly the PLC/DAG kinase system that can also generate PA). For the description of the measurement of PLD in this chapter, the substrates or the reaction are: [a] a special, short-chain PC (PC8) and [b] radiolabeled butanol. The reaction product is phosphatidyl-butanol (PBut) that is separated by TLC in a 'polar' solvent. This method was originally described in (27) .
Preparation of liposomes:
1. Label a small unsiliconized glass test tube 'liposomes'; rinse with ddH 2 O and dry.
2. Add 13.5 μl (final concentration 24 mM) of PC8 per condition to the tube.
3. Dry PC8 lipid under Nitrogen.
4.
Once dry, add 22.2 μl of 5 mM HEPES per condition to the tube.
Vortex vigorously.
6. Let sit for one hour at room temperature.
7.
Sonicate for 30 seconds in a bath sonicator; keep liposomes on ice until needed.
Preparation of the assay mix:
1. To a 2 ml eppendorf tube labeled 'assay mix', add the following per condition: 30 μl of 200 mM HEPES; 7.89 μl of [ 3 H]butanol and 12.1 μl of ddH 2 O.
Reaction and lipid separation:
At this point the enzyme (in cell sonicates) is ready to be mixed with the radiolabeled substrate in the optimal conditions of co-factors, ionic strength, pH, etc. 
2.
Include positive controls (cabbage PLD pure enzyme) and negative controls (PLD buffer instead of cell sonicates).
3.
Incubate 30 minutes at 30 °C in a slowly shaking incubator, agitate lightly during the hour.
4.
Stop the reaction by adding 3 ml of ice-cold chloroform/methanol (1:2, vol/vol) and 0.7 ml of 1% perchloric acid.
5.
Vortex for 1 minute and let sit for 10 minutes.
6. Add 1 ml of chloroform and 1 ml of 1% perchloric acid.
7.
Vortex for 1 minute, centrifuge and aspirate upper phase.
8. Wash lower phase with 2 ml of 1% perchloric acid.
9.
Vortex, centrifuge, and aspirate upper phase.
10.
Repeat wash if necessary.
11.
Collect lower phase for TLC (should be approximately 1 ml).
Isolation of reaction product (radiolabeled PBut):
1. Dip a TLC plate in 1.3% potassium oxalate for 1 minute.
2.
Let dry at room temperature.
3.
Heat plate at 115 °C for 1 hour; let it cool down.
4.
Dry samples under nitrogen.
5.
Add 25 μl of chloroform/methanol (95:5, vol/vol) to dried down sample and then immediately spot 25 μl on the TLC plate-repeat until all samples are spotted.
6. Spot 20 μl of PBut standard on each plate.
7.
Place the plate in the TLC chamber containing the 'PLD solvent system' (run takes approximately 55 minutes).
8.
Remove plate and let dry.
9.
Place plate in iodine chamber to visualize authentic standards.
10. Scrape 0.5 cm above and 2 cm below PBut (R f in this solvent system is ~ 0.45) (see Note 11).
11. Count radioactivity.
Immunoprecipitation and immunocomplex enzyme assays
The immunocomplex assay is an extra step that can be added prior to the in vitro microassays alluded above (Subheadings 3.1.2-3.1.4). This extra step relies on the inclusion of a specific antibody that will ensure that a particular isoform out of a collection of enzymes with similar reaction activities will be measured ( Figure 3 ).
In this chapter, a specific example is given for PLD2 isoform as we have described previously (28, 29) . The in vitro microassay described in 2.1.4 will measure total PLD in a sample, while immunoprecipitation with PLD2 antibody, as described below, will target that particular activity. This approach can be extrapolated to the study of PLA 2 or PLC isoforms, just by using the appropriate antibody.
3.2.1. Preparation of antibody conjugates-With this step the primary antibody will be bound to the secondary antibody (linked to agarose beads) forming the tertiary complex: [1ry/2ry/agarose] or 'antibody conjugate'. The following amounts are given for one experimental condition. For the experiment, multiply the amounts by the number of conditions and plan for one extra condition for negative controls, i.e., all reagents except the primary antibody. Note that the protocol given below is for PLD2, but it can be easily extrapolated to analyze isoforms of the other phospholipases (PLA 2 and PLC) simply by using the appropriate specific antibody against the isoform intended to be studied. All steps below must be performed at 4 °C.
1. Take 1.5 ml screw cap eppendorf tube labeled 'Ab conjugate' and place on ice; add 40 μl anti-mouse beads slurry.
2.
Add 100 μl LB to the tube, vortex gently and spin down at 12-13,000 rpm for 15 sec and discard supernatant (see Note 12). 11 We routinely use a long-chain analog of PC8-PBut since, as far as we can tell, there are not commercially available standards for PBut with the short, dioctanoyl chain (PC8). In the TLC system considered, the R f for PC8-PBut is located approximately one cm below the long-chain PBut (and actually close to phosphatidylethanol (PEt) that can be used as an alternative standard). 12 During all steps that require washes during the immunoprecipitation procedure, always pull off supernatant very carefully, leaving a small amount of liquid on the precipitate so as to avoid touching and unsettling the beads. Alternatively, the tube can be decanted, positioning it at a 45 degree angle with the mouth of the tube against a paper napkin/kimwipe. Never overdo it (it is better to leave some liquid on top of the beads pellet, forming a meniscus), since it is vital that beads remain at the bottom of the eppendorf and none are not lost.
The advantages of assaying phospholipases in intact cells are: [a] One can assay receptormediated activation. It is sometimes difficult to maintain the coupling in broken-cell preparations (enriched membrane fractions, whole lysates or sonicates); [b] if the conditions of the in vitro assays are set at optimal (as described previously), they certainly will detect all activity there is there, but it might not necessarily reflect what is happening in the intact cell. The phospholipase under study might be down-regulated in the intact cell, but not in the in vitro assay. In vitro microassays. From a common step that generates a 'cell sonicate' mixture the three phospholipases (PLA 2 , PLC and PLD) can be measured. The cell sonicates are incubated with the appropriate substrate (radiolabeled) and the product of the reaction is purified (normally by thin layer chromatography, TLC). Counting radioactivity at the end of the experiment provides cpm, that are a direct index of the phospholipase activity studied. (R1 and R2, generic fatty acid moieties in sn-1 and sn-2 positions; C20:4, arachidonoyl; C8:0, octanoyl; polar H. G., polar head group). Immunoprecipitation and immunocomplex enzyme assays. A specific antibody (linked to agarose beads) effectively isolates a particular phospholipase isoform (shown here PLD2) from a cell mix. The activity of the immunoprecipitated enzyme can be assayed then in vitro. Intact-cell or in vivo assays. Cultured or suspended cells are incubated with a radioactive precursor: either arachidonic acid, inorganic phosphate or myristic acid, for the measurement of PLA 2 , PLCβ or PLD, respectively. Once a steady state has been reached and the cellular lipids become labeled, cells are washed and stimulated with the agonist under study. This can cause the breakdown of the radiolabeled phospholipids and the release of either arachidonic acid, PIP 2 or phosphatidylpropanol, that are isolated and purified. (*, radiolabeled substrate; PL, phospholipid).
